Pathogenetic complexes in treatment of patients with viral respiratory infections

Elena N. Popova , Liubov A. Ponomareva , Alina A. Chinova

For citation:

Abstract

According to WHO, the share of acute respiratory infections (ARVI) is about 70–90% of all infectious diseases. Despite their relatively short-term course, they suffer significant economic damage due to high turnover among the population and temporary disability. Especially since the end of 2019, when SARS-Cov-2 infection has taken priority and the attention of the entire global medical community. ARVI is a heterogeneous group of infectious diseases of the respiratory system caused by a huge number of viruses (there are more than 200 of them, among them: influenza virus, parainfluenza, respiratory syncytial virus, adenovirus, coronavirus and others). The symptoms and pathogenesis of the disease are similar in many ways (fever, cough, chest pain, myalgia, asthenia, headaches, anosmia and others), but there are also differences. The article discusses in detail the symptoms of acute respiratory viral infections (including COVID-19) and medicines, their components, which are most widely used in the epidemic period, and also provides a pathogenetic justification for the use. During the epidemic period (in Russia it lasts from October to March-April), the demand for various medicines (drugs) among the population traditionally increases. Since ARVI belong to a group of diseases, in relation to which a large proportion of self-prescribing drugs and cases of self-medication, it is of interest to consider in more detail the various drugs and components of drugs from the point of view of the pathogenesis of the disease.

Key words: paracetamol, ascorbic acid, phenylephrine, COVID-19, acute respiratory infections.

References

1. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19): клинические рекомендации. Минздрав России. Версия 15 (22.02.2022). URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf

[Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19): klinicheskie rekomendatsii. Minzdrav Rossii. Versiia 15 (22.02.2022). URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (in Russian).]

2. Острые респираторные вирусные инфекции (ОРВИ) у взрослых. Клинические рекомендации. Минздрав России. 2021. URL: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2021/КР%20ОРВИ.pdf

[Ostrye respiratornye virusnye infektsii (ORVI) u vzroslykh. Klinicheskie rekomendatsii. Minzdrav Rossii. 2021. URL: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2021/KR ORVI.pdf (in Russian).]

3. Xu X, Yu C, Qu J et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020; 47 (5): 1275–80. DOI: 10.1007/s00259-020-04735-9

4. Hani C, Trieu NH, Saab I et al. COVID-19 pneumonia: A review of typical CT findings and differential diagnosis. Diagn Interv Imaging 2020; 101 (5): 263–8. DOI: 10.1016/j.diii.2020.03.014

5. Gül Ü. COVID-19 and dermatology. Turk J Med Sci 2020; 50 (8): 1751–9. DOI: 10.3906/sag-2005-182

6. Sisó-Almirall A, Brito-Zerón P, Conangla Ferrín L et al. On Behalf Of The CAMFiC Long Covid-Study Group. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. Int J Environ Res Public Health 2021; 18 (8): 4350. DOI: 10.3390/ijerph18084350

7. Grifoni A, Weiskopf D, Ramirez SI et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 2020; 181 (7): 1489–1501.e15. DOI: 10.1016/j.cell.2020.05.015

8. Larici AR, Cicchetti G, Marano R et al. Multimodality imaging of COVID-19 pneumonia: from diagnosis to follow-up. A comprehensive review. Eur J Radiol 2020; 131: 109217. DOI: 10.1016/j.ejrad.2020.109217

9. Puzyrenko A, Felix JC, Ledeboer NA et al. Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis. Pathology 2021; 2022; 54 (4): 404–8. DOI: 10.1016/j.pathol.2021.09.005

10. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 2020; 8 (8): 807–15. DOI: 10.1016/S2213-2600(20)30225-3

11. Wu LP, Wang NC, Chang YH et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis 2007; 13 (10): 1562–4. DOI: 10.3201/eid1310.070576

12. Chen P, Nirula A, Heller B et al; BLAZE-1 Investigators. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 2021; 384 (3): 229–37. DOI: 10.1056/NEJMoa2029849

13. Frieman M, Heise M, Baric R. SARS coronavirus and innate immunity. Virus Res 2008; 133 (1): 101–12. DOI: 10.1016/j.virusres.2007.03.015

14. Bastard P, Rosen LB, Zhang Q et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370 (6515): eabd4585. DOI: 10.1126/science.abd4585

15. Le Bert N, Tan AT, Kunasegaran K et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020; 584 (7821): 457–62. DOI: 10.1038/s41586-020-2550-z

16. Heald-Sargent T, Muller WJ, Zheng X et al. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). JAMA Pediatr 2020; 174 (9): 902–3. DOI: 10.1001/jamapediatrics.2020.3651

17. Smorenberg A, Peters EJ, van Daele P et al. How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity. Eur J Intern Med 2021; 83: 1–5. DOI: 10.1016/j.ejim.2020.11.024

18. Poletti P, Tirani M, Cereda D et al; ATS Lombardy COVID-19 Task Force. Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy. JAMA Netw Open 2021; 4 (3): e211085. DOI: 10.1001/jamanetworkopen.2021.1085

19. Norman DC. Fever in the elderly. Clin Infect Dis 2000; 31 (1): 148–51. DOI: 10.1086/313896

20. Guo T, Shen Q, Guo W et al. Clinical Characteristics of Elderly Patients with COVID-19 in Hunan Province, China: A Multicenter, Retrospective Study. Gerontology 2020; 66 (5): 467–75. DOI: 10.1159/000508734

21. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY) 2020; 12 (10): 9959–81. DOI: 10.18632/aging.103344

22. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2013; 2013 (1): CD000980. DOI: 10.1002/14651858.CD000980.pub4

23. Pascarella G, Strumia A, Piliego C et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020; 288 (2): 192–206. DOI: 10.1111/joim.13091

24. Wu X, Liu X, Zhou Y et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med 2021; 9 (7): 747–54. DOI: 10.1016/S2213-2600(21)00174-0

25. Коденцова В.М., Рисник Д.В., Никитюк Д.Б., Тутельян В.А. Витаминно-минеральные комплексы в лечебном питании. Consilium Medicum. 2017; 19 (12): 76–83. DOI: 10.26442/2075-1753_19.12.76-83

[Kodentsova V.M., Risnik D.V., Nikitiuk D.B., Tutel'ian V.A. Vitaminno-mineral'nye kompleksy v lechebnom pitanii. Consilium Medicum. 2017; 19 (12): 76–83. DOI: 10.26442/2075-1753_19.12.76-83 (in Russian).]

26. Gómez E, Quidel S, Bravo-Soto G, Ortigoza Á. Does vitamin C prevent the common cold? Medwave 2018; 18 (4): e7235. DOI: 10.5867/medwave.2018.04.7236

27. Quidel S, Gómez E, Bravo-Soto G, Ortigoza Á. What are the effects of vitamin C on the duration and severity of the common cold? Medwave 2018; 18 (6): e7261. DOI: 10.5867/medwave.2018.06.7260

28. Ran L, Zhao W, Wang J et al. Extra Dose of Vitamin C Based on a Daily Supplementation Shortens the Common Cold: A Meta-Analysis of 9 Randomized Controlled Trials. Biomed Res Int 2018; 2018: 1837634. DOI: 10.1155/2018/1837634

29. Abioye AI, Bromage S, Fawzi W. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis. BMJ Glob Health 2021; 6 (1): e003176. DOI: 10.1136/bmjgh-2020-003176

30. Shrestha DB, Budhathoki P, Sedhai YR et al. Vitamin C in Critically Ill Patients: An Updated Systematic Review and Meta-Analysis. Nutrients 2021; 13 (10): 3564. DOI: 10.3390/nu13103564

31. Hemilä H, Chalker E. Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis. Nutrients 2019; 11 (4): 708. DOI: 10.3390/nu11040708

32. Kwak SG, Choo YJ, Chang MC. The effectiveness of high-dose intravenous vitamin C for patients with coronavirus disease 2019: A systematic review and meta-analysis. Complement Ther Med 2022; 64: 102797. DOI: 10.1016/j.ctim.2021.102797

33. Rawat D, Roy A, Maitra S et al. Vitamin C and COVID-19 treatment: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr 2021; 15 (6): 102324. DOI: 10.1016/j.dsx.2021.102324

34. Hemilä H. Vitamin C intake and susceptibility to the common cold. Br J Nutr 1997; 77 (1): 59–72. DOI: 10.1017/s0007114500002889

35. Eccles R. Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. J Clin Pharm Ther 2006; 31 (4): 309–19. DOI: 10.1111/j.1365-2710.2006.00754.x

36. Brune K, Renner B, Tiegs G. Acetaminophen/paracetamol: A history of errors, failures and false decisions. Eur J Pain 2015; 19 (7): 953–65. DOI: 10.1002/ejp.621

37. Kantor TG. Ibuprofen. Ann Intern Med 1979; 91 (6): 877 82. DOI: 10.7326/0003-4819-91-6-877

38. Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther 2000; 22 (5): 500–48. DOI: 10.1016/S0149-2918(00)80043-0

39. Cooper SA. Comparative analgesic efficacies of aspirin and acetaminophen. Arch Intern Med 1981; 141 (3 Spec No): 282–5. DOI: 10.1001/archinte.141.3.282

40. Derry S, Wiffen PJ, Moore RA. Aspirin for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev 2017; 1 (1): CD011888. DOI: 10.1002/14651858.CD011888.pub2

41. Schachtel BP, Fillingim JM, Beiter DJ et al. Rating scales for analgesics in sore throat. Clin Pharmacol Ther 1984; 36 (2): 151–6. DOI: 10.1038/clpt.1984.154

42. Schachtel BP, Fillingim JM, Thoden WR et al. Sore throat pain in the evaluation of mild analgesics. Clin Pharmacol Ther 1988; 44 (6): 704–11. DOI: 10.1038/clpt.1988.215

43. Bachert C, Chuchalin AG, Eisebitt R et al. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study. Clin Ther 2005; 27 (7): 993–1003. DOI: 10.1016j.clinthera.2005.06.002

44. Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. Arch Pediatr Adolesc Med 2004; 158 (6): 521–6. DOI:10.1001/archpedi.158.6.521

45. Schachtel BP, Thoden WR. A placebo-controlled model for assaying systemic analgesics in children. Clin Pharmacol Ther 1993; 53 (5): 593–601. DOI:10.1038/clpt.1993.75

46. Cranswick N, Coghlan D. Paracetamol efficacy and safety in children: the first 40 years. Am J Ther 2000; 7 (2): 135–41. DOI:10.1097/00045391-200007020-00010

47. Зайцева О.В. Современные возможности профилактики и лечения острых респираторных заболеваний. РМЖ. 2011; 19 (23): 1458–61. URL: https://elibrary.ru/download/elibrary_20168443_81663491.pdf

[Zaitseva O.V. Sovremennye vozmozhnosti profilaktiki i lec

For citation:Popova e.n., Ponomareva L.A., chinova A.A. Pathogenetic complexes in treatment of patients with viral respiratory infections. clinical review for general practice. 2022; 2: 25–32. doI: 10.47407/kr2022.3.2.00123

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice